Sarepta’s Duchenne Gene Therapy Update Gets Bullish Stance From Analysts
Sarepta Therapeutics Inc (NASDAQ:SRPT) reported above-consensus 2Q FY22 product sales of $211 million and provided more details on the path forward…
Novo Nordisk Shares Fall After Q2 Earnings Despite Raised Annual Outlook
Novo Nordisk A/S (NYSE:NVO) reported Q2 sales of DKK41.27 billion, +25% Y/Y (+15% on a constant currency basis). Operating profit…
Amarin Still Suspends FY22 Guidance On Generic Challenges
Amarin Corporation plc (NASDAQ:AMRN) continues suspending 2022 revenue guidance citing the ongoing global impact of COVID-19, the uncertainty resulting from the…
Regeneron’s Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $9.77 per share for Q2 FY22, down 62% Y/Y, beating the $9.54 estimate. Sales decreased…
Merrimack Pharma-Ipsen’s Cancer Drug Fails In Overall Survival Measure
Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK) partner announced that Ipsen SA (OTC:IPSEY) reported a primary analysis of the results of the…
Horizon Therapeutics’ Shares Tumble On Q2 Miss, Trimmed FY22 Outlook
Horizon Therapeutics plc’s (NASDAQ:HZNP) reported Q2 sales of $876.4 million, +5% Y/Y, missing the consensus of $936.10 million. The adjusted…
Alnylam Shares Shoot Higher Following Positive Clinical Results From Late-Stage ATTR Amyloidosis Therapeutics
Alnylam (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of Patisiran for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
FDA Accepts MediWound’s Refiling For Severe Thermal Burns Therapy For Review
The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ: MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.
Kiniksa Inks Global License Agreement With Roche For Vixarelimab
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) has announced a global license agreement with Roche Holdings AG (OTC:RHHBY) and Genentech to develop and commercialize vixarelimab, a fully human…
Merck’s Two Keytruda Combo Cancer Trials Miss Primary Goal
Merck & Co Inc’s (NYSE:MRK) Phase 3 KEYNOTE-921 trial of Keytruda combined with chemotherapy (docetaxel) did not meet its dual…